DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome–associated myeloid leukemia
Authors:
- Lonneke J. VerboonLVLonneke J. Verboon
- Sonali P. BarweSBSonali P. Barwe
- Joshua R. FaustJFJoshua R. Faust
- José Gonçalves-DiasJGJosé Gonçalves-Dias
- Konstantin SchuschelKSKonstantin Schuschel
- Raj BhayadiaRBRaj Bhayadia
- Aimy SebastianASAimy Sebastian
- Rhonda E. RiesRRRhonda E. Ries
- Sophie PaczesnySPSophie Paczesny
Open Access
- 23 June 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (12) , 4120-4133
Abstract
Children with Down syndrome have a markedly increased risk of developing myeloid leukemia. Although having an excellent prognosis, 10% to 20% develop relapsed or refractory disease with poor survival, highlighting the need for new targeted approaches. The pathogenesis of myeloid leukemia of Down syndrome (ML-DS) is tightly linked to fetal hematopoiesis and mutations in GATA1, generating the truncated GATA1 short (GATA1s) isoform. We identified Delta-like noncanonical Notch ligand 1 (DLK1) as a direct GATA1s target. DLK1, a paternally imprinted transmembrane protein, is highly expressed in fetal liver CD34+ cells but absent in adult hematopoiesis, making it an attractive immunotherapeutic target. Chromatin profiling revealed GATA1s occupancy at a distal enhancer within the DLK1-DIO3 locus, driving aberrant DLK1 upregulation in ML-DS. Functional studies demonstrated that DLK1 is a leukemia dependency, as its genetic ablation impaired proliferation and engraftment, induced apoptosis, and altered Notch and β-catenin signaling. Therapeutically, a DLK1-directed antibody-drug conjugate–induced selective cytotoxicity, abrogated colony formation, and significantly prolonged survival in refractory ML-DS patient-derived xenograft (PDX) models, achieving durable remissions at higher doses. These findings establish DLK1 as a leukemia-specific vulnerability and provide preclinical proof-of-concept for DLK1-targeted therapies in ML-DS and other leukemias with fetal-like expression programs.Keywords
All Related Versions
This publication has 59 references indexed in Scilit:
- A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaCancer Cell, 2024
- Mechanistic insights into the developmental origin of pediatric hematologic disordersExperimental Hematology, 2024
- Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndromePediatric Blood & Cancer, 2024
- Down syndrome and leukemia: An insight into the disease biology and current treatment optionsBlood Reviews, 2023
- Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15iScience, 2023
- Leukemia Risk in a Cohort of 3.9 Million Children with and without Down SyndromeThe Journal of Pediatrics, 2021
- Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down SyndromeCancer Cell, 2019
- Possible roles of DLK1 in the Notch pathway during development and diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activitiesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Fetal antigen 1 (FA1) in the human pancreas: cell type expression, topological and quantitative variations during developmentBrain Structure and Function, 1993